Nasdaq
$4.90▼ 0.20%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $19.9MShares out 4.1M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
17- 5d agoPre-market26.10.20 19:46SCHEDULE 13GOwnership#●●●
NextCure, Inc.
JP Sailing Capital Ltd and Jianping Huang have filed a Schedule 13G regarding their joint beneficial ownership of NextCure, Inc. common stock. JP Sailing Fund is the direct holder of the securities, with JP Sailing Capital Ltd acting as the investment manager and Jianping Huang reporting as a control person.…more
$4.90-0.20%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.1Pre-market26.10.01 08:36filedS-4/AOffering
NextCure, Inc.
NextCure has filed an S-4/A registration statement to proceed with the merger and acquisition of Avere Therapeutics. Additionally, Avere established a collaboration framework for drug development by entering into a license agreement with Shanghai Hansoh on June 15, 2026, and a clinical supply agreement on September 23, 2026.…more
$4.90-0.20%vs prev closeView filingShare - 9.25After-hours26.09.26 05:12425Other
NextCure, Inc.
NextCure has filed a petition in the Delaware Court of Chancery to validate its 1:12 reverse stock split, which became effective on July 14, 2025, due to legal uncertainty regarding the voting standard applied at the time. This action aims to confirm the validity of its capital structure ahead of the proposed merger with Avere Therapeutics, with a court hearing scheduled for November 6, 2026.…more
$4.90-0.20%vs prev closeView filingShare
16 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 8.6After-hours26.08.07 05:01#●●●
넥스트큐어, 2026년 2분기 실적 및 사업 현황 발표
넥스트큐어가 2026년 2분기 실적과 함께 주요 사업 진행 상황을 업데이트했습니다. 투자자들은 이번 발표를 통해 회사의 재무 건전성과 향후 파이프라인 개발 전략을 확인할 수 있습니다.…more
$4.90-0.20%vs prev closeDetected5m · 30m · 60m · Next dayPLUS